Developing safe and effective COVID vaccines — Operation Warp speed’s strategy and approach

26 August 2020 - Announced on May 15, Operation Warp Speed— a partnership of the Department of Health and Human ...

Read more →

As COVID-19 pressures mount, political newcomer Stephen Hahn struggles to protect an FDA under siege

24 August 2020 - Stephen Hahn, a political novice who moved here in December to take over the FDA, has ...

Read more →

An ‘America first’ pharma supply chain sounds good. But it won’t work.

17 June 2020 - With a stroke of the president’s Executive Order pen, the Trump administration awarded a $354 million, ...

Read more →

The Lancet, New England Journal retract COVID-19 studies, including one that raised safety concerns about malaria drugs

4 June 2020 - The Lancet, one of the world’s top medical journals, on Thursday retracted an influential study that ...

Read more →

The CDC waited its entire existence for this moment. What went wrong?

3 June 2020 - Americans returning from China landed at U.S. airports by the thousands in early February, potential carriers ...

Read more →

‘Vaccine nationalism’: a new dynamic in the race to quash coronavirus

27 May 2020 - International pursuit for a shot is shifting into a contest of which world power can immunise its ...

Read more →

Modelling epidemics with compartmental models

27 May 2020 - During epidemics, there is a critical need to understand both the likely number of infections and their ...

Read more →

How the world’s premier public health agency was handcuffed

23 May 2020 - The CDC has been absent with leave during the spread of COVID-19. ...

Read more →

What to expect when a coronavirus vaccine finally arrives

20 May 2020 - Sobering lessons from the history of the polio vaccine. ...

Read more →

COVID-19 raises questions about the value of personalised medicine

8 May 2020 - A group of medical dissenters argues that tailoring treatment to the genetic profiles of individuals, a longstanding ...

Read more →

Will Gilead price its coronavirus drug for public good or company profit?

7 May 2020 - Gilead faces a new dilemma in deciding how much it should profit from the only treatment so ...

Read more →

Remdesivir helps coronavirus patients — but at what cost?

6 May 2020 - Drug maker Gilead is known for creating breakthrough drugs and selling them at a premium. ...

Read more →

How remdesivir, new hope for COVID-19 patients, was resurrected

4 May 2020 - The drug failed as a treatment for hepatitis and Ebola. With federal funding, scientists trained it on ...

Read more →

Two potential therapies for COVID-19 have some effect

4 May 2020 - Hope rears its head, but more information is needed. ...

Read more →

The race for coronavirus vaccines: a graphical guide

28 April 2020 - Eight ways in which scientists hope to provide immunity to SARS-CoV-2. ...

Read more →